ATE496943T1 - Biotinylierte mhc-komplexe und ihre verwendungen - Google Patents

Biotinylierte mhc-komplexe und ihre verwendungen

Info

Publication number
ATE496943T1
ATE496943T1 AT07101561T AT07101561T ATE496943T1 AT E496943 T1 ATE496943 T1 AT E496943T1 AT 07101561 T AT07101561 T AT 07101561T AT 07101561 T AT07101561 T AT 07101561T AT E496943 T1 ATE496943 T1 AT E496943T1
Authority
AT
Austria
Prior art keywords
mhc complexes
biotinylated mhc
biotinylated
multimerising
immobilizing
Prior art date
Application number
AT07101561T
Other languages
English (en)
Inventor
Nikolai Franz Gregor Schwabe
Catherine Elizabeth Napper
Original Assignee
Prolmmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolmmune Ltd filed Critical Prolmmune Ltd
Application granted granted Critical
Publication of ATE496943T1 publication Critical patent/ATE496943T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/32—Post-translational modifications [PTMs] in chemical analysis of biological material biotinylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT07101561T 2006-07-25 2007-02-01 Biotinylierte mhc-komplexe und ihre verwendungen ATE496943T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0614735A GB2442048B (en) 2006-07-25 2006-07-25 Biotinylated MHC complexes and their uses

Publications (1)

Publication Number Publication Date
ATE496943T1 true ATE496943T1 (de) 2011-02-15

Family

ID=37006102

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07101561T ATE496943T1 (de) 2006-07-25 2007-02-01 Biotinylierte mhc-komplexe und ihre verwendungen

Country Status (6)

Country Link
US (2) US20080038282A1 (de)
EP (1) EP1882700B1 (de)
AT (1) ATE496943T1 (de)
DE (1) DE602007012176D1 (de)
DK (1) DK1882700T3 (de)
GB (1) GB2442048B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3878922B2 (ja) * 2003-04-24 2007-02-07 独立行政法人科学技術振興機構 脂質セカンドメッセンジャー検出・定量用プローブとそれを用いた脂質セカンドメッセンジャーの検出および定量方法
JP5779599B2 (ja) * 2010-02-17 2015-09-16 ワン ラムダ， インコーポレイテッド 天然ヒト白血球抗原に対する抗体を検出するための組成物および方法
CN103857691A (zh) * 2011-04-29 2014-06-11 俄克拉何马大学董事会 选择性抗hla抗体去除装置及其生产方法和用途
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
EP3365453A2 (de) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Verfahren, kits, mittel und vorrichtungen zur transduktion
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US11965892B2 (en) 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
KR20240091046A (ko) 2018-12-21 2024-06-21 바이오엔테크 유에스 인크. Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
EP4175664A2 (de) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostata-neoantigene und ihre verwendungen
CN112125959B (zh) * 2020-10-10 2022-07-29 中山大学肿瘤防治中心 一种抑制eb病毒的肽和编码该肽的dna及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US5252466A (en) * 1989-05-19 1993-10-12 Biotechnology Research And Development Corporation Fusion proteins having a site for in vivo post-translation modification and methods of making and purifying them
DE4237113B4 (de) * 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
CA2140591A1 (en) * 1994-01-20 1995-07-21 Josef Endl Antigen-specific, activated t lymphocytes, detection and use
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US20020151707A1 (en) * 1995-06-07 2002-10-17 Corixa Corp. Immune mediators and related methods
EP0868521A2 (de) * 1995-12-22 1998-10-07 Somatogen Inc. Globinen mit bindenden domänen
EP0917570A2 (de) * 1996-08-05 1999-05-26 The President And Fellows Of Harvard College Mhc-bindende peptid-oligomere und verfahren zur verwendung
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
DE19641876B4 (de) * 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
US6248564B1 (en) * 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US8609436B2 (en) * 2000-03-17 2013-12-17 Guy's & St Thomas' Hospital NHS Trust (“GST”) Method
US20030166277A1 (en) * 2000-04-12 2003-09-04 University Of Rochester Targeted vaccine delivery systems
US20020082411A1 (en) * 2001-01-23 2002-06-27 Darrick Carter Immune mediators and related methods
DE10117858A1 (de) * 2001-04-10 2002-10-24 Gsf Forschungszentrum Umwelt MHC-Tetramere
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
US6902921B2 (en) * 2001-10-30 2005-06-07 454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
GB0202018D0 (en) * 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
US20040132133A1 (en) * 2002-07-08 2004-07-08 Invitrogen Corporation Methods and compositions for the production, identification and purification of fusion proteins
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
GB2408507B (en) * 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
GB2424645B (en) * 2005-04-01 2007-06-06 Proimmune Ltd Method of producing a set of MHC molecules

Also Published As

Publication number Publication date
EP1882700A1 (de) 2008-01-30
DE602007012176D1 (de) 2011-03-10
US20080038282A1 (en) 2008-02-14
GB0614735D0 (en) 2006-09-06
GB2442048B (en) 2009-09-30
US20150031566A1 (en) 2015-01-29
GB2442048A (en) 2008-03-26
EP1882700B1 (de) 2011-01-26
DK1882700T3 (da) 2011-05-16

Similar Documents

Publication Publication Date Title
ATE496943T1 (de) Biotinylierte mhc-komplexe und ihre verwendungen
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
DE602006021441D1 (de) Schlauch zur beförderung von kryogenen fluiden
CY2016004I2 (el) ΜΟΡΙΑ ΠΡΟΣΔΕΣΗΣ ΑΝΤΙΓΟΝΟΥ ΜΕ ΑΥΞΗΜΕΝΗ ΣΥΓΓΕΝΕΙΑ ΠΡΟΣΔΕΣΗΣ ΣΤΟΝ ΥΠΟΔΟΧΕΑ Fc ΚΑΙ ΛΕΙΤΟΥΡΓΙΑ ΤΕΛΕΣΤΗ
NL2000141A1 (nl) Oppervlaktelichtbron welke gebruik maakt van een LED en rugverlichtingseenheid welke de oppervlaktelichtbron heeft.
DE602007009373D1 (de) Kombination aus einem anti-edb-fibronectin-domänen-antikörper/il2-fusionsprotein und einem weiteren kleinen molekül
DE602007001728D1 (de) Hängefahrzeugsystem und Transportverfahren damit
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
DE602006015793D1 (de) Proteolipidmembran und lipidmembranen-biosensor
DE602007005044D1 (de) Fahrzeugbeleuchtungsvorrichtung
DK2345576T3 (da) Køretøj med låsbart tippesystem
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
MA28989B1 (fr) MOLECULES Fc MODIFIEES
EP3505687C0 (de) Koppler und mit kopplern ausgestattete fahrzeuge
EP2258967A4 (de) Gleitlager sowie automobil-zahnstangenlenkvorrichtung damit
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
ATE537183T1 (de) Hiv-fusionshemmerpeptide mit verbesserten biologischen eigenschaften
EP1902356A4 (de) Kriminologische integrierte suchtechnologie
DE602006012131D1 (de) Pedalsystem und Fahrzeug mit Pedalsystem
DE602006000779D1 (de) Planetenreibradantriebsvorrichtung und Lenkeinrichtung mit einer solchen
EP1875237A4 (de) Docetaxel-immuntest
EP1993447A4 (de) Molekularer ultraschallsensor und dessen verwendungen
DK1864129T3 (da) Doxurubicin-immunassay
DE502006006095D1 (de) Fahrzeugkran mit Ballastierung
EP1912921A4 (de) Verbindungen auf tetraazaporphyrinbasis und deren verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties